surmount-1 trial tirzepatide obesity without diabetes Demonstrates 94% Reduction, 22% Weight Loss in SURMOUNT -1 Study SURMOUNT-3 study design This is

Tirzepatide-related ADEs were more frequently observed in females (68.8%) compared to males (19%)

A randomized, controlled trial of oral propranolol in infantile hemangioma

If you want to understand how tirzepatide dosing is tied to long-term results, our article on a full dose of tirzepatide for sustainable weight management is a helpful next read

Some women notice changes in cycle timing, flow, or regularity while taking tirzepatide

ACS Nano 15 (7), 1234212357

Testosterone effects across the GLP-1 class A 2025 systematic review and meta-analysis examining GLP-1 RA effects on testosterone found consistent increases in total testosterone across multiple agents and studies